Novocure to Report Third Quarter 2021 Financial Results

Rhea-AI Summary

Novocure (NASDAQ: NVCR) will report its third quarter 2021 financial results on October 28, 2021, before U.S. markets open. A conference call is scheduled for 8 a.m. EDT on the same day to discuss the results for the three and nine months ended September 30, 2021. Participating analysts and investors can join by dialing the provided numbers. Novocure focuses on oncology, particularly with its Tumor Treating Fields (TTFields), aimed at treating aggressive cancers like glioblastoma. The company also has numerous clinical trials ongoing across various cancers.

Positive

• Upcoming earnings report expected to provide insights into financial performance.
• Focus on innovative therapy, Tumor Treating Fields, shows potential for market growth.

Negative

• None.

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2021 on Thursday, October 28, 2021, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three and nine months ended September 30, 2021, at 8 a.m. EDT on Thursday, October 28, 2021. Analysts and investors can participate in the conference call by dialing 855-442-6895 for domestic callers and 509-960-9037 for international callers, using the conference ID 6394785.

The webcast, earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields (TTFields). TTFields are electric fields that disrupt cancer cell division. Novocure’s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about us, visit Novocure.com and follow @Novocure on LinkedIn and Twitter.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 25, 2021 with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005311/en/

Investors:

Ingrid Goldberg

investorinfo@novocure.com

610-723-7427

Media:

Leigh Labrie

media@novocure.com

610-723-7428

Source: Novocure

FAQ

When will Novocure report its third quarter 2021 results?

Novocure will report its third quarter 2021 results on October 28, 2021.

What time is Novocure's earnings conference call?

The conference call is set for 8 a.m. EDT on October 28, 2021.

How can investors participate in Novocure's earnings call?

Investors can participate by calling 855-442-6895 for domestic or 509-960-9037 for international calls using conference ID 6394785.

What is Novocure's focus in oncology?

Novocure focuses on developing the Tumor Treating Fields therapy for aggressive forms of cancer.

Where can I access Novocure's earnings presentation?

The earnings presentation can be accessed live from Novocure's Investor Relations page on their website.